CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| EA3211 | ECOG-ACRIN | Phase III Randomized Trial of Immunotherapy with or without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma | Adult CIRB - Late Phase Emphasis | Available to Open |
| NSABP-B-49 | NSABP | A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative; HER2-Negative Breast Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
| NRG-GI005 | NRG | Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA) | Adult CIRB - Late Phase Emphasis | Available to Open |
| PBTC-061 | PBTC | Phase 2 Trial of G207 + 5 Gy Radiation for Children with High-Grade Gliomas | Pediatric CIRB | Available to Open |
| S1801 | SWOG | A Phase II Randomized Study of Adjuvant versus Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Sage III-IV High Risk Melanoma | Adult CIRB - Late Phase Emphasis | Available to Open |
| EA2165 | ECOG-ACRIN | A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
| 10132 | ETCTN | A Phase I Study of the Wee 1 kinase (Wee 1) inhibitor AZD1775 in combination with Radiotherapy and Cisplatin in Cervical, Upper Vaginal and Uterine Cancers (10041848, 10008224, 10008238, 10046888, 10014735) | Adult CIRB - Early Phase Emphasis | Available to Open |
| NRG-GY025 | NRG | A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients with Deficient Mismatch Repair System Recurrent Endometrial Carcinoma | Adult CIRB - Late Phase Emphasis | Available to Open |
| 10486 | ETCTN | Phase 2 Trial of the Combination of the BET inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET) | Adult CIRB - Early Phase Emphasis | Available to Open |
| S1933 | SWOG | A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status | Adult CIRB - Late Phase Emphasis | Available to Open |